Area of research
Molecular Medicine · Pharmacology
Research interest
Research interests include Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Use and Resistance, and Vibrio bacteria research studies.
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials.
<i>Enterobacter hormaechei</i> co-harbouring <i>bla</i> <sub>KPC-2</sub>, <i>bla</i> <sub>VIM-24</sub>, and <i>bla</i> <sub>NDM-1</sub>: the rise of the 'unholy trinity'.
<i>In vitro</i> activity of cefepime/zidebactam against <i>Klebsiella pneumoniae</i> carrying <i>bla</i> <sub>KPC</sub> variants conferring resistance to ceftazidime/avibactam.
Sulbactam-durlobactam and cefiderocol combination treatment of <i>Burkholderia cenocepacia</i>-associated Fitz-Hugh-Curtis syndrome.
Role of Ambler Position 104 in Defining Substrate Specificity in the KPC Family of β-Lactamases.
Response to "The promise and pitfalls: interpreting dual β-lactam success in <i>Mycobacterium abscessus</i> with caution".
Synergistic activity of dual β-lactams against <i>Mycobacterium avium</i> complex.
Structural and Kinetic Basis for the Rational Design of Next-Generation β-Lactamase Inhibitors.
Cryptic Binding Pockets in PDC‑3 β‑Lactamase Modulate Resistance Profiles.
Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying <i>bla</i><sub>OXA-48</sub>.
A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol.
A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates with diverse phenotypic and genotypic resistance mechanisms.
Optimizing target inactivation to treat multidrug-resistant <i>Escherichia coli</i> with NDM and PBP3 mutations: "going the extra mile".
Impact of <i>Pseudomonas aeruginosa</i> biofilm exopolysaccharide composition on bacteriophage and bacteriophage-antibiotic combination activity.
Zinc starvation uncovers bacterial host-specific proteases that shape NDM adaptability in <i>Acinetobacter baumannii</i>.
Vitamin B12 promotes cefiderocol resistance and small-colony variants in carbapenem-resistant <i>Acinetobacter baumannii</i>.
Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant <i>Pseudomonas aeruginosa</i> and clinical implications in the prospective observational <i>Pseudomonas</i> study.
OXA β-lactamases from <i>Acinetobacter</i> spp. are membrane bound and secreted into outer membrane vesicles.
A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of <i>Acinetobacter</i> spp.
β-Lactamase diversity in <i>Acinetobacter baumannii</i>.
β-Lactamase diversity in <i>Pseudomonas aeruginosa</i>.
Durlobactam in combination with β-lactams to combat <i>Mycobacterium abscessus</i>.
Cefiderocol "under siege"? Understanding the rise of NDM-mediated resistance to novel agents.
Emerging resistance to novel β-lactam β-lactamase inhibitor combinations in Klebsiella pneumoniae bearing KPC variants
Repurposing a drug to punish carbapenem-resistant <i>Acinetobacter baumannii</i>
Carbapenem-resistant Enterobacterales in solid organ transplant recipients
Revisiting REVISIT: The Case for Ceftazidime/Avibactam Plus Aztreonam.
SAND: a comprehensive annotation of class D β-lactamases using structural alignment-based numbering.
Resistance to oxyimino-cephalosporins conferred by an alternative mechanism of hydrolysis by the <i>Acinetobacter</i>-derived cephalosporinase-33 (ADC-33), a class C β-lactamase present in carbapenem-resistant <i>Acinetobacter baumannii</i> (CR<i>Ab</i>).
Cefepime-Taniborbactam-a Novel Combination Therapy for Multidrug-Resistant Pathogens.